SANOFI S.A.

ISIN: FR0000120578 WKN: 12057 Asset Class: Stock

E-mail: -



Company Profile

75017 Paris

Total assets

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Financial figures, Fiscal year: from 01.01. to 31.12. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 30,655,000,000 34,026,000,000 30,564,000,000 Common stock capital 2,530,000,000 2,522,000,000 2,527,000,000 **Fixed assets** 95,809,000,000 92,696,000,000 89,678,000,000 Equity capital of a company 74,353,000,000 75.152.000.000 69.031.000.000 Cash and cash equivalents 8.710.000.000 12.736.000.000 10.098.000.000 Accrued liabilities 5,262,000,000 5.822.000.000 6,430,000,000 Other assets **Current liabilities** 24,194,000,000 23,964,000,000 21,295,000,000 Prepayments and accrued income Non-current liabilities 27,917,000,000 27,606,000,000 29,916,000,000 Different income Other liabilities 4 696 000 000 3 182 000 000 2,907,000,000

126,464,000,000

126,722,000,000

126,722,000,000

120,242,000,000

120,242,000,000

126,464,000,000

Balance notes			
	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	87,994	91,573	95,442
Equity ratio	59.04%	59.60%	57.70%
Debt-equity ratio	69.37%	67.80%	73.31%
Others			
	2023	2022	2021
Tax Expense Rate	22.40%	19.25%	19.98%

SANOFI S.A.

ISIN: FR0000120578 WKN: 12057 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	43,070,000,000	42,997,000,000	37,761,000,000
Net income	5,400,000,000	8,371,000,000	6,223,000,000
EBIT	7,701,000,000	10,660,000,000	8,171,000,000
Operating income before taxes	7,153,000,000	10,422,000,000	7,798,000,000
Cash Flow	10,258,000,000	10,526,000,000	10,522,000,000
Net interest income	-548,000,000	-238,000,000	-373,000,000
Research and development expenses	6,725,000,000	6,705,000,000	5,689,000,000
Income taxes	1,602,000,000	2,006,000,000	1,558,000,000
Result from investments in subsidaries, associates and other	-115,000,000	68,000,000	39,000,000
Revenues per employee	489,465	469,538	395,643

Board of Directors	
Frédéric Oudéa	Chairman of Supervisory Board
Antoine Yver	Member of Supervisory Board
Emile Voest	Member of Supervisory Board
John Sundy	Member of Supervisory Board
Wolfgang Laux	Member of Supervisory Board
Anne-Francoise Nesmes	Member of Supervisory Board
Barbara Lavernos	Member of Supervisory Board
Carole Ferrand	Member of Supervisory Board
Christophe Babule	Member of Supervisory Board
Clotilde Delbos	Member of Supervisory Board
Fabienne Lecorvaisier	Member of Supervisory Board
Gilles Schnepp	Member of Supervisory Board
Lise Kingo	Member of Supervisory Board
Patrick Kron	Member of Supervisory Board
Rachel Duan	Member of Supervisory Board
Yann Tran	Member of Supervisory Board

Members of Management Board		
Paul Hudson	Chairman of Managing Board	
Brendan O'Callaghan	Member of Executive Committee	
Brian Foard	Member of Executive Committee	
Emmanuel Frenehard	Member of Executive Committee	
Francois Roger	Member of Executive Committee	
Houman Ashrafian	Member of Executive Committee	
Julie Van Ongevalle	Member of Executive Committee	
Madeleine Roach	Member of Executive Committee	
Natalie Bickford	Member of Executive Committee	
Olivier Charmeil	Member of Executive Committee	
Roy Papatheodorou	Member of Executive Committee	
Thomas Triomphe	Member of Executive Committee	